Frontiers in immunology · 2024
Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sha Sumei, Xu Bin, Wang Kairuo, Qiao Chenyang, Shi Haitao, Jiang Jiong, Quan Xiaojing, Liu Xin
Аннотация
BACKGROUND: The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians.
CASE PRESENTATION: In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.
CONCLUSION: This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.
CASE PRESENTATION: In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.
CONCLUSION: This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.